Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MDxHealthMDXH -4.85%45 3-Year EBITDA Growth Rate is 49.80% as of Jun. 2026, which is 211% above its 10-year median of 16.00. GuruFocus rates MDXH with a GF Score™ of 45/100 and a GF Value™ of $2.11 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, MDxHealth ranks better than 83.23% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 49.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 35.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 17.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of MDxHealth was 49.80% per year. The lowest was -38.50% per year. And the median was 16.00% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
MDxHealth 3-Year EBITDA Growth Rate Related Terms
MDXH vs PRPO, IDXGD, BNR: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, MDxHealth's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where MDxHealth's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 49.80% mean?
MDxHealth (MDXH) has a 3-Year EBITDA Growth Rate of 49.80% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MDxHealth and its competitors. This is 211% above median its historical median of 16.00. According to the industry distribution chart, MDxHealth ranks #28 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 16.8%.
Is MDxHealth's 3-Year EBITDA Growth Rate too high?
MDxHealth's current 3-Year EBITDA Growth Rate of 49.80% is 211% above median its 10-year median of 16.00. The Medical Diagnostics & Research industry median 3-Year EBITDA Growth Rate is 11.00. MDxHealth's value of 49.80% is 352.7% above this industry median. Based on the distribution chart, MDxHealth ranks #28 out of 167 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, MDxHealth has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's 3-Year EBITDA Growth Rate compare to PRPO and IDXGD?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #28 out of 167 companies for 3-Year EBITDA Growth Rate. This places MDxHealth in the top 17% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 11.00. MDxHealth's value of 49.80% is 352.7% above this benchmark. While the company's 10-year median is 16.00 vs. the industry median of 11.00, MDxHealth has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MDxHealth's current 3-Year EBITDA Growth Rate of 49.80% is 352.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for MDxHealth and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MDxHealth's current 3-Year EBITDA Growth Rate is 49.80%, which is 211% above median its own 10-year median of 16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.11, compared to a current price of $0.71 — trading 66.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 49.80%, which is 211% above median its 10-year median of 16.00 and 352.7% above the Medical Diagnostics & Research industry median of 11.00. MDxHealth's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For MDxHealth (MDXH), the current 3-Year EBITDA Growth Rate is 49.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (MDXH) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of $0.71 is trading 66.4% below its estimated GF Value™ of $2.11.
GuruFocus considers MDxHealth to be Possible Value Trap.
Key valuation signals for MDXH:
3-Year EBITDA Growth Rate: 49.80% (211% above median its 10-year median of 16.00)
GF Value™: $2.11 vs. price of $0.71 (66.4% below fair value)
Industry Position: 352.7% above the Medical Diagnostics & Research median (#28 of 167)
No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
45GF Score
Get the complete analysis for MDXH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXH has been successfully added to your 
